Press Releases

Year

Jul 27 2017

Intec Pharma Promotes Nadav Navon, Ph.D. to Chief Operating Officer

JERUSALEM, July 27, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ (AP) platform technology, announces the promotion of Nadav Navon, Ph.D., Executive Vice

Jul 19 2017

Intec Pharma Granted Patent in Hong Kong for Accordion Pill™ Carbidopa / Levodopa

JERUSALEM, July 19, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the Patent Registry Intellectual Property Department of Hong Kong has

Jul 19 2017

Intec Pharma Granted Patent in Hong Kong for Accordion Pill™ Carbidopa / Levodopa

JERUSALEM, July 19, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill [ TM ] platform technology, announces that the Patent Registry Intellectual Property Department of Hong

Jul 10 2017

Intec Pharma Appoints U.S. Life Sciences Executive and Vice Chairman Jeffrey A. Meckler as Chief Executive Officer

JERUSALEM, July 10, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the appointment of Jeffrey A.

May 31 2017

Intec Pharma to Participate at Upcoming June Conferences

Intec Pharma Ltd. (Nasdaq:NTEC)(TASE:NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the company will participate at the following two upcoming June conferences: LD Micro Invitational Date and

May 24 2017

Intec Pharma Granted U.S. Patent for Accordion Pill™ Comprising Levodopa for Improved Treatment of Parkinson's Diseases Symptoms

JERUSALEM, May 24, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the United States Patent and Trademark Office has granted the Company patent

May 03 2017

Intec Pharma Announces CEO Change

JERUSALEM, May 3, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that Zeev Weiss, Chief Executive Officer and a Director of the Company,

Apr 09 2017

Intec Pharma Appoints U.S. Life Sciences Executive Jeffrey A. Meckler to its Board of Directors as Vice Chairman

JERUSALEM, April 9, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced the appointment of Jeffrey A.

Apr 07 2017

Intec Pharma Reports 2016 Fourth Quarter and Full Year Financial Results

JERUSALEM, April 7, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq and TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today reported financial results for the three and 12 months ended December 31,

Mar 29 2017

Intec Pharma Provides Update on Phase III ACCORDANCE Study of the Accordion Pill Carbidopa/Levodopa in Parkinson's Disease Patients

Expects to Complete Enrollment in the Fourth Quarter of 2017 JERUSALEM, March 29, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq; TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today provided an

First page
Previous page
…
Page 2
Page 3
Page 4
Page 5
Current page 6
Page 7
Page 8
Page 9
Page 10
Next page
Last page

Displaying 51 - 60 of 91